Everyone's pointing fingers at everyone else. There's a lack of information, there's a lack of transparency. And one of the things … Having more transparency, more disclosure, more reporting [in the drug pricing and supply chain system] is a critical first step. … where you think transparent, more transparency is most needed? Well, I think with Commissioner Hodak, I was nodding in agreement. So I want to be clear there. (32:23–32:42)
CLAIM
Asserts that increased transparency, disclosure, and reporting are essential first steps to address excessive drug prices.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
